NasdaqGM:AQSTPharmaceuticals
Assessing Aquestive Therapeutics (AQST) Valuation After The FDA Complete Response Letter For Anaphylm
Why the FDA’s Complete Response Letter Matters for Aquestive
Aquestive Therapeutics (AQST) has drawn fresh attention after the FDA issued a Complete Response Letter for its Anaphylm epinephrine sublingual film, prompting the company to schedule a special call to discuss the regulatory feedback.
See our latest analysis for Aquestive Therapeutics.
The FDA letter appears to have been the catalyst for a sharp shift in sentiment, with a 1 day share price return of 38.98% and a 7 day share price...